JP2023513704A5 - - Google Patents

Info

Publication number
JP2023513704A5
JP2023513704A5 JP2022548599A JP2022548599A JP2023513704A5 JP 2023513704 A5 JP2023513704 A5 JP 2023513704A5 JP 2022548599 A JP2022548599 A JP 2022548599A JP 2022548599 A JP2022548599 A JP 2022548599A JP 2023513704 A5 JP2023513704 A5 JP 2023513704A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
erdafitinib
patient
fgfr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022548599A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513704A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2021/053385 external-priority patent/WO2021160764A1/en
Publication of JP2023513704A publication Critical patent/JP2023513704A/ja
Publication of JP2023513704A5 publication Critical patent/JP2023513704A5/ja
Priority to JP2026034354A priority Critical patent/JP2026097934A/ja
Withdrawn legal-status Critical Current

Links

JP2022548599A 2020-02-12 2021-02-11 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤 Withdrawn JP2023513704A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026034354A JP2026097934A (ja) 2020-02-12 2026-03-04 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202062975547P 2020-02-12 2020-02-12
US62/975,547 2020-02-12
US202063018914P 2020-05-01 2020-05-01
US63/018,914 2020-05-01
US202063118475P 2020-11-25 2020-11-25
US63/118,475 2020-11-25
PCT/EP2021/053385 WO2021160764A1 (en) 2020-02-12 2021-02-11 Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026034354A Division JP2026097934A (ja) 2020-02-12 2026-03-04 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤

Publications (2)

Publication Number Publication Date
JP2023513704A JP2023513704A (ja) 2023-04-03
JP2023513704A5 true JP2023513704A5 (cg-RX-API-DMAC7.html) 2024-02-21

Family

ID=74666675

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022548599A Withdrawn JP2023513704A (ja) 2020-02-12 2021-02-11 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤
JP2026034354A Pending JP2026097934A (ja) 2020-02-12 2026-03-04 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026034354A Pending JP2026097934A (ja) 2020-02-12 2026-03-04 高リスク筋層非浸潤性膀胱癌を治療するためのfgfrチロシンキナーゼ阻害剤

Country Status (14)

Country Link
US (1) US20230110113A1 (cg-RX-API-DMAC7.html)
EP (1) EP4103185A1 (cg-RX-API-DMAC7.html)
JP (2) JP2023513704A (cg-RX-API-DMAC7.html)
KR (1) KR20220140781A (cg-RX-API-DMAC7.html)
CN (1) CN115103678A (cg-RX-API-DMAC7.html)
AU (1) AU2021220285A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022015827A2 (cg-RX-API-DMAC7.html)
CA (1) CA3162962A1 (cg-RX-API-DMAC7.html)
IL (1) IL295514A (cg-RX-API-DMAC7.html)
JO (1) JOP20220182A1 (cg-RX-API-DMAC7.html)
MX (1) MX2022009905A (cg-RX-API-DMAC7.html)
PH (1) PH12022552093A1 (cg-RX-API-DMAC7.html)
TW (1) TW202143970A (cg-RX-API-DMAC7.html)
WO (1) WO2021160764A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312063A (en) * 2021-10-12 2024-06-01 Taris Biomedical Llc Ardafitinib formulations and systems for intravesical administration
JP2025506402A (ja) * 2022-02-04 2025-03-11 ヤンセン ファーマシューティカ エヌ.ベー. 転移性去勢抵抗性前立腺癌及びhrr変化を有する患者における臨床アウトカムを改善するためのニラパリブ及び酢酸アビラテロン+プレドニゾン
WO2023159216A1 (en) * 2022-02-18 2023-08-24 Taris Biomedical Llc Erdafitinib formulations and osmotic systems for intravesical administration
IL322667A (en) * 2023-02-13 2025-10-01 Taris Biomedical Llc Ardepitinib for intravesical administration for use in the treatment of bladder cancer
KR20250148646A (ko) * 2023-02-13 2025-10-14 얀센 파마슈티카 엔브이 고위험 비근침윤성 방광암 치료를 위한 fgfr 티로신 키나제 억제제
CN120731077A (zh) * 2023-02-17 2025-09-30 塔里斯生物医药公司 膀胱内施用厄达替尼以用于治疗膀胱癌
CN121891539A (zh) * 2026-02-06 2026-04-21 深圳大学 一种靶向iCAFs亚群的FGF2抑制剂组合物及其在膀胱癌防治中的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
CA2744096C (en) 1996-07-31 2013-07-30 Laboratory Corporation Of America Holdings Biomarkers and targets for diagnosis, prognosis and management of prostate disease
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
EP2270000B1 (en) 2005-05-23 2015-07-29 Novartis AG Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one lactic acid salts
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
SG11201702381QA (en) * 2014-09-26 2017-04-27 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
TWI719960B (zh) * 2015-02-10 2021-03-01 英商阿斯迪克治療公司 新穎組成物
CA3049737A1 (en) * 2017-02-06 2018-08-09 Janssen Pharmaceutica Nv Cancer treatment
MA47408B1 (fr) * 2017-12-20 2023-08-31 Janssen Pharmaceutica Nv Traitement du cancer

Similar Documents

Publication Publication Date Title
Stadler et al. A phase II study of depsipeptide in refractory metastatic renal cell cancer
Goldberg et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial.
US9486445B2 (en) Combination therapy for proliferative disorders
AU2016244279B2 (en) Method of adjuvant cancer treatment
EA037152B1 (ru) Способ лечения рака
WO2017201156A1 (en) Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab
JP2006501147A5 (cg-RX-API-DMAC7.html)
AU2018234903B2 (en) Combination therapies for the treatment of breast cancer
JP2025156297A (ja) 尿路上皮癌の治療のためのfgfrチロシンキナーゼ阻害剤
EP1750713B1 (en) Use of imatinib to treat liver disorders and viral infections
JP2022534118A5 (cg-RX-API-DMAC7.html)
HUP0204139A2 (en) Use of n-[6-methoxi-5-(2-methoxiphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]-2phenyl-etienesulfonamide for producing pharmaceutical composition using for reducing pain in an endothelin-induced disease
TW202034921A (zh) 癌症療法
WO2007083119A2 (en) Methods
CN113260363A (zh) 格拉普兰特(grapiprant)单位剂型
KR20230043598A (ko) 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염 및 항바이러스제를 유효성분으로 함유하는 코로나바이러스감염증-19(covid-19) 치료용 조성물
TW200412971A (en) Therapeutic treatment
KR101741281B1 (ko) 건선 치료를 위한 a3 아데노신 수용체 작동약 (ib-meca/cf-101)을 포함하는 제약학적 조성물
WO2020248240A1 (zh) 痘苗病毒致炎兔皮提取物治疗癌症的用途
TW202300145A (zh) 藥物組合、包含其的試劑盒及其用途
CN120752038A (zh) 瑞普替尼治疗胃肠道基质瘤的方法
CN112004525A (zh) 注射用组合物
George et al. 4517 POSTER Sunitinib in patients with cytokine-refractory metastatic renal cell carcinoma (mRCC)
CN116847842A (zh) Irak4降解剂和其用途
KR20230027226A (ko) 화학요법-유발 설사를 치료하기 위한 방법 및 조성물